Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "BIAL Pharmaceuticals"

15:20 EDT 24th July 2014 | BioPortfolio

Original Source: Bial and Eisai

Founded in 1924, Bial is an international pharmaceutical group with products available in over 30 countries throughout four continents. BIAL is the largest Portuguese pharmaceutical company and is based in S. Mamede do Coronado, Portugal.

Matching Channels

None

Matching News

moksha8 to commercialize BIAL’s eslicarbazepine in Brazil And Mexico

Portuguese drugmaker BIAL and Brazil-based moksha8 have entered an exclusive license for the commercialization of eslicarbazepine acetate (Zebinix/Exalief) in Brazil and Mexico for the treatment of ep...

BIAL, moksha8 partner to commercialize Eslicarbazepine Acetate in Brazil and Mexico

BIAL, a research based international pharmaceutical company, and moksha8, a leading specialty pharmaceutical company in Latin America, have announced an exclusive license for the commercialization of...

Partial Seizure Global Clinical Trials Review, H2, 2014

Recently added to the BioPortfolio report store, Partial Seizure Global Clinical Trials Review, H2, 2014 is a new report from GlobalData published on 2014-07-13. This 181-page report is available in...

BIAL And moksha8 Announce Exclusive License For The Commercialization Of Eslicarbazepine Acetate (Zebinix® / Exalief®) In Brazil And Mexico

WAYNE, Pa. and PORTO, Portugal, July 15, 2014 /PRNewswire/ -- BIAL, a research based international pharmaceutical company, and moksha8, a leading specialty pharmaceutical company in Lat...

Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022

Recently added to the BioPortfolio report store, Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022 is a new report from GlobalData published on 2014-04-29. This 87-pag...

Once-Daily Aptiom® (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies

Sunovion Pharmaceuticals Inc. (Sunovion) announced that Aptiom® (eslicarbazepine acetate), a once-daily antiepileptic drug (AED) indicated for use as adjunctive treatment of part...

Opicapone (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Recently added to the BioPortfolio report store, Opicapone (Parkinson’s Disease) - Forecast and Market Analysis to 2022 is a new report from GlobalData published on 2014-03-30. This 86-page report...

Postherpetic Neuralgia - Pipeline Review, H1 2014

Recently added to the BioPortfolio report store, Postherpetic Neuralgia - Pipeline Review, H1 2014 is a new report from Global Markets Direct published on 2014-03-30. This 108-page report is availabl...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement